臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

關於TAIR
	計畫說明

瀏覽
	典藏機構
	作者
	題名
	日期
	統計圖表
	機構即時統計
	學術趨勢

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作權
	出版社及期刊政策查詢
	TAIR著作權會議記錄

相關連結
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"ying chun shen"的相關文件

回到依作者瀏覽
依題名排序	依日期排序

顯示項目 11-35 / 38 (共2頁)
1 2 > >>
每頁顯示[10|25|50]項目

機構	日期	題名	作者
臺大學術典藏	2021-03-09T05:18:39Z	Lack of efficacy of troglitazone at clinically achievable concentrations, with or without 9-cis retinoic acid or cytotoxic agents, for hepatocellular carcinoma cell lines	Ying-Chun Shen; Hsu C.; Chen J.-Y.; Cheng A.-L.
臺大學術典藏	2021-03-09T05:18:38Z	Molecular targeted therapy for advanced hepatocellular carcinoma	Ying-Chun Shen; Hsu C.; Cheng A.L.
臺大學術典藏	2021-03-09T05:18:38Z	Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma	Ou D.-L.; Ying-Chun Shen; Liang J.-D.; Liou J.-Y.; Yu S.-L.; Fan H.-H.; Wang D.-S.; Lu Y.-S.; Hsu C.; Cheng A.-L.
臺大學術典藏	2021-03-09T05:18:38Z	Sorafenib for the treatment of hepatocellular carcinoma across geographic regions	Hsu C.; Ying-Chun Shen; Cheng A.L.
臺大學術典藏	2021-03-09T05:18:38Z	Molecular subtypes of breast cancer emerging in young women in Taiwan: Evidence for more than just westernization as a reason for the disease in Asia	Lin C.-H.; Liau J.-Y.; Lu Y.-S.; Huang C.-S.; Lee W.-C.; Kuo K.-T.; Ying-Chun Shen; Kuo S.-H.; Lan C.; Liu J.M.; Kuo W.-H.; Chang K.-J.; Cheng A.-L.
臺大學術典藏	2021-03-09T05:18:37Z	Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma	Hsu C.-H.; Ying-Chun Shen; Lin Z.-Z.; Chen P.-J.; Shao Y.-Y.; Ding Y.-H.; Hsu C.; Cheng A.-L.
臺大學術典藏	2021-03-09T05:18:37Z	Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B	Ko B.-S.; Chang T.-C.; Chen C.-H.; Liu C.-C.; Kuo C.-C.; Hsu C.; Ying-Chun Shen; Shen T.-L.; Golubovskaya V.M.; Chang C.-C.; Shyue S.-K.; Liou J.-Y.
臺大學術典藏	2021-03-09T05:18:37Z	Geographic difference in survival outcome for advanced hepatocellular carcinoma: Implications on future clinical trial design	Hsu C.; Ying-Chun Shen; Cheng C.-C.; Hu F.-C.; Cheng A.-L.
臺大學術典藏	2021-03-09T05:18:36Z	Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma	Shao Y.-Y.; Lin Z.-Z.; Hsu C.; Ying-Chun Shen; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-03-09T05:18:36Z	Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): A meta-regression approach	Ying-Chun Shen; Hsu C.; Chen L.-T.; Cheng C.-C.; Hu F.-C.; Cheng A.-L.
臺大學術典藏	2021-03-09T05:18:36Z	Molecular targeted therapy for advanced hepatocellular carcinoma: Current status and future perspectives	Ying-Chun Shen; Hsu C.; Cheng A.-L.
臺大學術典藏	2021-03-09T05:18:35Z	Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil	Hsu C.-Y.; Ying-Chun Shen; Yu C.-W.; Hsu C.; Hu F.-C.; Hsu C.-H.; Chen B.-B.; Wei S.-Y.; Cheng A.-L.; Shih T.T.-F.
臺大學術典藏	2021-03-09T05:18:35Z	Induction of DNA damage-inducible gene GADD45�] contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells	Ou D.-L.; Ying-Chun Shen; Yu S.-L.; Chen K.-F.; Yeh P.-Y.; Fan H.-H.; Feng W.-C.; Wang C.-T.; Lin L.-I.; Hsu C.; Cheng A.-L.
臺大學術典藏	2021-03-09T05:18:34Z	A critical evaluation of the preventive effect of antiviral therapy on the development of hepatocellular carcinoma in patients with chronic hepatitis C or B: A novel approach by using meta-regression	Ying-Chun Shen; Hsu C.; Cheng C.-C.; Hu F.-C.; Cheng A.-L.
臺大學術典藏	2021-03-09T05:18:34Z	Targeting fibroblast growth factor receptor signaling in hepatocellular carcinoma	Cheng A.-L.; Ying-Chun Shen; Zhu A.X.
臺大學術典藏	2021-03-09T05:18:34Z	Antiangiogenic strategies for the treatment of hepatocellular carcinoma	Hsu C.; Ying-Chun Shen; Cheng A.-L.
臺大學術典藏	2021-03-09T05:18:34Z	High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy	Shao Y.-Y.; Lin Z.-Z.; Chen T.-J.; Hsu C.; Ying-Chun Shen; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-03-09T05:18:33Z	Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems	Shao Y.-Y.; Lu L.-C.; Lin Z.-Z.; Hsu C.; Ying-Chun Shen; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-03-09T05:18:33Z	Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: A meta-analysis and meta-regression	Hsu C.; Ying-Chun Shen; Cheng C.-C.; Cheng A.-L.; Hu F.-C.; Yeh K.-H.
臺大學術典藏	2021-03-09T05:18:32Z	Phase ii multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer	Ying-Chun Shen; Li C.-P.; Yen C.-J.; Hsu C.; Lin Y.-L.; Lin Z.-Z.; Chen L.-T.; Su W.-C.; Chao Y.; Yeh K.-H.; Cheng A.-L.
臺大學術典藏	2021-03-09T05:18:32Z	erratum: Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: A meta-analysis and meta-regression (Gastric Cancer (2012) 15(265-280) DOI 10.1007/s10120-011- 0106-5)	Hsu C.; Ying-Chun Shen; Cheng C.-C.; Cheng A.-L.; Hu F.-C.; Yeh K.-H.
臺大學術典藏	2021-03-09T05:18:32Z	Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma	Ying-Chun Shen; Ou D.-L.; Hsu C.; Lin K.-L.; Chang C.-Y.; Lin C.-Y.; Liu S.-H.; Cheng A.-L.
臺大學術典藏	2021-03-09T05:18:31Z	Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma	Lu L.-C.; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Ying-Chun Shen; Guo J.-C.; Liu T.-H.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-03-09T05:18:31Z	Considerations of heterogeneity in clinical trials for hepatocellular carcinoma	Liu T.-H.; Shao Y.-Y.; Lu L.-C.; Ying-Chun Shen; Hsu C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-03-09T05:18:31Z	Combining intratumoral Treg depletion with androgen deprivation therapy (ADT): Preclinical activity in the Myc-CaP model	Ying-Chun Shen; Ghasemzadeh A.; Kochel C.M.; Nirschl T.R.; Francica B.J.; Lopez-Bujanda Z.A.; Carrera Haro M.A.; Tam A.; Anders R.A.; Selby M.J.; Korman A.J.; Drake C.G.

顯示項目 11-35 / 38 (共2頁)
1 2 > >>
每頁顯示[10|25|50]項目

	English \| 正體中文 \| 简体中文 \| 總筆數 :0
	造訪人次 : 52647133 線上人數 : 883 教育部委託研究計畫計畫執行:國立臺灣大學圖書館